Segment disclosures

Company overview

Exicure, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 18 retained observations 12 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Biotechnology Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=xcur:BiotechnologySegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261120Open filing evidence
2026-01-01 – 2026-09-300 USD20261120Open filing evidence
2026-04-01 – 2026-06-300 USD20260814Open filing evidence
2026-01-01 – 2026-06-300 USD20260814Open filing evidence
2026-01-01 – 2026-03-310 USD20260529Open filing evidence
2025-01-01 – 2025-12-310 USD20260325Open filing evidence
2025-07-01 – 2025-09-300 USD20261120Open filing evidence
2025-01-01 – 2025-09-300 USD20261120Open filing evidence
2025-04-01 – 2025-06-300 USD20260814Open filing evidence
2025-01-01 – 2025-06-300 USD20260814Open filing evidence
2025-01-01 – 2025-03-310 USD20260529Open filing evidence
2024-01-01 – 2024-12-31500000 USD20260325Open filing evidence
2024-07-01 – 2024-09-300 USD20251107Open filing evidence
2024-01-01 – 2024-09-30500000 USD20251107Open filing evidence
2024-04-01 – 2024-06-300 USD20250808Open filing evidence
2024-01-01 – 2024-06-30500000 USD20250808Open filing evidence
2024-01-01 – 2024-03-31500000 USD20250627Open filing evidence
2023-01-01 – 2023-12-310 USD20250318Open filing evidence